A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report

BACKGROUND: Osimertinib is a novel and irreversible epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeting EGFR sensitive mutations and EGFR exon20 p.T790M mutation, which demonstrated superior progression-free survival (PFS) and overall survival (OS). CASE PRESENTATION: W...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Sun, Yanwei, Pei, Lina, Luo, Ningning, Chen, Dongsheng, Meng, Lingxin
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646409/
https://ncbi.nlm.nih.gov/pubmed/33173309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S267524
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados